Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mesoblast Ltd (NASDAQ:MESO)

4.28
Delayed Data
As of Jul 26
 -0.02 / -0.47%
Today’s Change
3.50
Today|||52-Week Range
15.00
-32.70%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$328.0M

Company Description

Mesoblast Ltd. engages in the development of bio-therapeutics based on its proprietary cell-based and protein technologies. Its proprietary cell-based core technologies include highly purified, immunoselected Mesenchymal Precursor Cells (MPCs), culture-expanded Mesenchymal Stem Cells (MSCs), Dental Pulp Stem Cells (DPSCs), and expanded Hematopoietic Stem Cells (HSCs). Its protein technologies are based on factors derived from its proprietary cellular platforms, including Stromal Derived Factor-1 (SDF-1). The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Contact Information

Mesoblast Ltd.
Level 38
Melbourne Victoria (vic) 3000
P:(139) 639-6036
Investor Relations:

Employees

Shareholders

Mutual fund holders2.63%
Other institutional1.82%
Individual stakeholders--

Top Executives

Silviu ItescuChief Executive Officer, Executive Director & MD
Paul HodgkinsonChief Financial Officer
Donna L. SkerrettChief Medical Officer
Susan Elizabeth MacLemanHead-Commercialization
Jonathan Richard SymondsHead-Corporate Finance & Strategy